Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.64 and traded as high as $0.7190. Brainstorm Cell Therapeutics shares last traded at $0.70, with a volume of 15,865 shares traded.
Brainstorm Cell Therapeutics Price Performance
The business has a fifty day moving average of $0.60 and a 200 day moving average of $0.64. The stock has a market cap of $7.83 million, a PE ratio of -0.21 and a beta of 0.69.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical?stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Featured Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
